Eli Lilly and Viking Therapeutics both operate in the high-growth field of obesity drugs.

Novo Nordisk has global metabolic leadership, an oral GLP-1 program, and a stock price below $50 after a retail-driven ...

Novo Nordisk stock moved higher after oral Wegovy logged over 18,000 first-week prescriptions, with Goldman Sachs boosting sentiment via a Buy rating.

It feels like a great rotation out of the Magnificent Seven has already kicked off just over a quarter ago. Undoubtedly, the ...

We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...

While numerous growth stocks have faced recent pressure, Eli Lilly has demonstrated notable resilience. This stability is ...

Eli Lilly and Co (NYSE: LLY) has outperformed the market over the past 5 years by 25.43% on an annualized basis producing an ...

Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the French press that pharmaceutical giant Eli Lilly ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Alumis, Aktis Oncology, and W.R. Berkley saw significant insider buying last week. There were a handful of other notable ...

Price target rises to $275 from Jefferies. Company partners with Lilly on $1B AI drug lab. Analysts see stock trading cheap.

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...